From: Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity
Target | Agent | Putative/intended mechanism of action | Developmental status |
---|---|---|---|
CD19 | MD1342 (fully human) | B-cell depletion | Phase I for RA, trial suspended |
 | CD19 chimeric antigen receptors |  | Phase I/II for B-cell malignancies |
 | Blinatumomab |  |  |
 | XmAb5574/MOR208 |  |  |
 | MEDI-551 |  |  |
CD20 | Rituximab (chimeric) | Â | Approved for use in NHL, RA and ANCA vasculitides |
 | Ocrelizumab (humanized) |  | Phase III for RRMS and PPMS |
 | Veltuzumab (humanized) |  | Phase III for RA, phase I/II for AITP |
 | Ofatumumab (fully human) |  | Phase III for RA, phase I/II for RRMS |
CD22 | Epratuzumab (humanized) | Blockade of CD22 - partial depletion of B cells, inhibition of activation, proliferation, survival of B cells | Phase III for SLE |
CD52 | Anti-CD52 or Campath-1h, Alemtuzumab | Depletion of T cells and B cells | Phase III for MS, phase II for autoimmune cytopenias, phase I for inclusion body myositis, phase I/II for RA not continueda |